Physician profile
Robert L Dodd
NPI 1134276777
$8,582.60
in general payments reported to CMS, 2019-2025
7 companies · $515 in 2025
The $515 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $191 · 2021: $112 · 2022: $2,125 · 2023: $4,520 · 2024: $489 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,250 · Food and Beverage: $968 · Travel and Lodging: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,250.00 |
| Food and Beverage | $968.32 |
| Travel and Lodging | $305.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $6,066.33 | 2019-2025 | Surpass Evolve, Axs Vecta 71, Evolve |
| Siemens Medical Solutions USA, INC. | $1,886.51 | 2022 | |
| Microvention, INC. | $300.52 | 2019-2020 | |
| Penumbra, INC. | $136.66 | 2019 | |
| Nx Development Corp. | $109.25 | 2019 | |
| Integra Lifesciences Corporation | $83.33 | 2025 | Trudi Probe, Relieva Spinplus Nav, Inspira Air |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$26,220.48 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dodd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.